Nasdaq
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Alpha Teknova, Inc. provides critical reagents for life sciences market in the United States and internationally. Its reagents enable the discovery, development, and production of biopharmaceutical products. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion.
Roles derived from SEC Form 4 filings.
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $31.3M | $36.9M | $41.4M | $36.7M | $37.7M | $40.5M |
| Gross profit | $17.8M | $17.6M | $17.5M | $10.3M | $7.2M | $13.4M |
| Operating income | $4.7M | -$12.0M | -$49.7M | -$35.6M | -$26.1M | -$17.0M |
| Net income | $3.6M | -$9.8M | -$47.5M | -$36.8M | -$26.7M | -$17.3M |
| Diluted EPS | $0.16 | -$0.61 | -$1.69 | -$1.16 | -$0.57 | -$0.32 |
| Operating cash flow | $2.5M | -$9.1M | -$27.4M | -$18.8M | -$12.4M | -$8.6M |
| Free cash flow | -$3.0M | -$28.9M | -$55.5M | -$26.7M | -$13.5M | -$9.8M |
| Gross margin | 56.7% | 47.8% | 42.2% | 28.1% | 19.2% | 33.2% |
| Operating margin | 14.9% | -32.5% | -119.9% | -96.9% | -69.3% | -41.9% |
| Net margin | 11.4% | -26.6% | -114.6% | -100.3% | -70.9% | -42.6% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $9.6M | $9.6M | $9.3M | $9.8M | $10.3M | $10.5M | $10.0M | $11.1M |
| Gross profit | $2.8M | $90,000.00 | $2.1M | $3.0M | $4.0M | $3.2M | $3.2M | $3.8M |
| Operating income | -$5.1M | -$7.4M | -$5.6M | -$5.0M | -$3.4M | -$4.0M | -$4.6M | -$4.3M |
| Net income | -$5.4M | -$7.6M | -$5.7M | -$4.6M | -$3.6M | -$4.3M | -$4.8M | -$4.6M |
| Diluted EPS | -$0.13 | -$0.15 | -$0.09 | -$0.09 | -$0.07 | -$0.08 | -$0.08 | -$0.08 |
| Operating cash flow | -$2.8M | -$2.1M | -$936,000.00 | -$4.1M | -$2.1M | -$2.0M | -$462,000.00 | -$3.4M |
| Free cash flow | -$3.0M | -$2.4M | -$1.5M | -$4.3M | -$2.3M | -$2.4M | -$810,000.00 | -$3.6M |
| Gross margin | 29.2% | 0.9% | 23.0% | 30.7% | 38.7% | 30.7% | 32.5% | 34.2% |
| Operating margin | -53.0% | -77.6% | -60.7% | -50.7% | -32.9% | -38.4% | -46.2% | -38.8% |
| Net margin | -55.8% | -79.0% | -61.7% | -47.4% | -34.7% | -41.0% | -47.7% | -41.1% |
Consensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-14 | DEMSKI MARTHA J | J | 12,000 | $0.00 | $0.00 | filing |
| 2026-07-14 | DEMSKI MARTHA J | J | 12,000 | $0.00 | $0.00 | filing |
| 2026-03-06 | Lowell Matthew· Chief Financial Officer | Buy | 40,000 | $2.19 | $87,616.00 | filing |
| 2026-03-06 | Gunstream Stephen· President and CEO | Buy | 26,000 | $2.15 | $55,801.20 | filing |
| 2025-06-27 | DEMSKI MARTHA J | Sale | 8,000 | $5.06 | $40,512.00 | filing |
| 2025-06-17 | Vos Alexander | Award | 54,300 | $0.00 | $0.00 | filing |
| 2025-06-17 | ROBERTSON BRETT | Award | 54,300 | $0.00 | $0.00 | filing |
| 2025-06-17 | DEMSKI MARTHA J | Award | 54,300 | $0.00 | $0.00 | filing |
Latest 8 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.